SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* BAUM MARK L (Last) (First) (Middle) (Street) (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Imprimis Pharmaceuticals, Inc. [ IMMY ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner X Officer (give title below) Other (specify below) Chief Executive Officer
	3. Date of Earliest Transaction (Month/Day/Year) 06/29/2012
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(2)	06/29/2012		C		7,498,500	A	$0	15,738,545	I	DermaStar(1)
Common Stock(3)	07/12/2012		J		846,927	A	$0	846,927	D
Common Stock(4)	07/18/2012		A		800,000	A	$0	1,646,927	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Convertible Preferred Stock	$0.0013	07/12/2012		C			10	(5)	(5)	Common Stock	7,498,500	$0	0	I	DermaStar(1)

Explanation of Responses:

1. DermaStar International, LLC ("DermaStar") was the direct beneficial owner of such shares of the Issuer's capital stock, prior to its distribution of such shares to its members on July 12, 2012 pursuant to the terms of its operating agreement. The reporting person is a managing member of DermaStar and holds an ownership interest in DermaStar, and as a managing member of DermaStar may be deemed to have voting and dispositive power over the shares of the Issuer's capital stock owned by DermaStar. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

2. Shares of Common Stock issued upon conversion of ten (10) shares of Series A Convertible Preferred Stock of the Issuer held by DermaStar at the election of DermaStar and in consideration of the Issuer's payment of an aggregate amount of $200,000 to DermaStar to induce such conversion, pursuant to the terms of a conversion agreement between DermaStar and the Issuer dated June 29, 2012.

3. Shares of Common Stock distributed by DermaStar to its members, including the reporting person, pursuant to the terms of DermaStar's operating agreement, and to certain additional individuals, on July 12, 2012.

4. Represents a restricted stock unit that settles in common stock of the Company, which is subject to certain performance-based vesting criteria such that 200,000 shares will vest upon the satisfaction of each of the following events: (i) successful completion of a financing that results in aggregate cash proceeds to the Company of at least $5,000,000 at any time following the effective date of the grant; (ii) the Company meets the primary endpoints of its Phase III clinical studies for Impracor; (iii) the Company submits a New Drug Application for Impracor to the U.S. Food and Drug Administration; and (iv) the Company enters into a definitive license, collaboration or similar agreement for Impracor that would reasonably be expected to generate cash flow for the Company.

5. Each share of Series A Convertible Preferred Stock of the Issuer is convertible into 749,850 shares of the Common Stock of the Issuer at any time at the option of DermaStar, the holder of such shares, pursuant to the terms and subject to adjustment as set forth in the Certificate of Designation of Series A Convertible Preferred Stock of the Issuer.

	/s/ Mark L. Baum	07/20/2012
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.